Sarepta Therapeutics: Pfizer-Versagen beseitigt Überhang - Aktienanalyse
London (www.aktiencheck.de) - Sarepta Therapeutics-Aktienanalyse von Barclays:
Gena Wang, Analystin von Barclays, nimmt in einer aktuellen Aktienanalyse die Aktie von Sarepta…
49,485€
-6,95%
Echtzeit-Aktienkurs Sarepta Therapeutics Inc.
Bid:
Ask:
Nachrichten zur Sarepta Therapeutics Inc. Aktie
Sarepta Therapeutics to replace Shockwave Medical in the S&P MidCap 400
…
Mizuho raises Sarepta Therapeutics stock target on FDA hopes By Investing.com
Mizuho raises Sarepta Therapeutics stock target on FDA hopes…
Sarepta Therapeutics (SRPT) Q1 2024 Earnings Call Transcript
SRPT earnings call for the period ending March 31, 2024.…
Sarepta Therapeutics, Inc. (SRPT) Q1 2024 Earnings Call Transcript
…
Sarepta Therapeutics: Growth Trajectory Alters Trading Strategy
…
Sarepta Therapeutics: Another Hold Call Ahead Of Some Key Catalysts
…
5 Small Biotech ETFs to Watch (Updated 2024)
Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. Biotech ETFs allow market participants…
Sarepta Therapeutics Stock Has 73% Upside, According to 1 Wall Street Analyst
The upcoming regulatory decision on its latest drug could be big.…
UBS raises Sarepta Therapeutics shares target on label outlook By Investing.com
UBS raises Sarepta Therapeutics shares target on label outlook…
Sarepta Therapeutics (SRPT) Q4 2023 Earnings Call Transcript
SRPT earnings call for the period ending December 31, 2023.…
Sarepta Therapeutics, Inc. (SRPT) Q4 2023 Earnings Call Transcript
…
Is It Too Late to Buy Sarepta Therapeutics Stock?
The companys hyperfocus on its core area could continue to be highly lucrative.…